Document:

Exhibit 10.1

 

EMPLOYMENT AGREEMENT

  

This Employment Agreement
(“Agreement”) is made and entered into this 1st day of October, 2019, by and between Tristan R. Farel (“Farel”),
LTN ERGY, LLC (“LTN”) (Farel and LTN are collectively “LTN”), and Samson Oil and Gas Limited (the “Client”).
LTN and the Client are referred to herein sometimes in the singular as a “Party” and collectively as the “Parties.”
The Parties agree as follows:

 

		1.	Services and Compensation. The Client retains
LTN to provide the services of Farel to act as Chief Financial Officer and shall provide support to Client for those duties that
are customary of a Chief Financial Officer beginning on October 1, 2019, (the “Commencement Date”).

 

For
Services rendered Client shall pay LTN compensation in the amount of $240,000 per annum until this Agreement is terminated.

 

Client
shall permit LTN to participate in the Client’s health benefits program during the term of this Agreement.

 

LTN
shall be named under Client’s Directors and Officers insurance plan during the term of this Agreement.

 

		2.	Term, Renewal. This Agreement shall be effective from the Commencement Date hereof with
a minimum term of 12 months (“Initial Term”) and shall continue indefinitely, thereafter, until terminated in accordance
with the terms of this Agreement. This Agreement may be amended from time to time.

 

		3.	Termination Either party may terminate this agreement after the Initial Term for any reason
at any time by giving 30 day prior written notice of such termination. LTN shall be paid for Services performed up to and including
the effective date of termination of this Agreement.

 

		4.	Independent Contractor. LTN is an independent contractor for all purposes under this Agreement.
As an independent contractor, LTN shall determine the details, methods, and means of performing the Services under this Agreement.
Provided, however, that Farel shall perform the Services in conformity with any policies or directions given from time to time
by the CEO or board of directors of the Client. The Client shall be responsible for providing LTN with the information necessary
to perform the Services under this Agreement in a timely manner.

 

 

		5.	Taxes. LTN is obligated to pay its own payroll taxes, including without limitation, worker’s
compensation, unemployment compensation, social security, retirement pensions or benefits or other charges that are required to
be made with respect to or measured by the wages and salaries of persons employed by LTN that are imposed by or under the laws
of either the United States or other jurisdiction in which the work is performed and federal and state taxes on any monies earned.
No such payments will be withheld or paid by the Client. LTN indemnifies the Client against all liability or expense due to LTN’s
failure to pay proper taxes.

 

     

     

    

 

		6.	Work Product. The Client shall have complete and unrestricted right to use all documents,
reports and data compilations prepared or produced by LTN in connection with LTN’s performance of the Services under this
Agreement (“Work Product”). Such Work Product shall become the property of the Client and shall not be used by LTN
for any other project or purpose without the Client’s prior written consent. Upon request from the Client, all materials
containing such Work Product shall be delivered to the Client, at the Client’s expense. Notwithstanding anything to the Contrary,
LTN expressly retains the right to refuse to release any Work Product to the Client if the Client is in default in its payment
for Services, until such time as the default is rectified.

 

		7.	Nondisclosure of Confidential Information. In the performance of the Services, LTN will
have access to confidential or proprietary information, including without limitation, confidential or proprietary information concerning
the Services, the Work Product and the Client’s business activities (collectively “Confidential Information”).
LTN undertakes to not use any such Confidential Information except in connection with the Services and to not disclose or release
such Confidential Information to any third party without the Client’s prior written consent. The foregoing undertaking shall
not apply to (i) information in the possession of LTN at the date of this Agreement; or (ii) information which is in publicly available,
other than through disclosure by LTN.

 

		8.	Indemnity, Release. The Client shall defend, indemnify and hold harmless LTN from and against
all damages, claims, liabilities and third party claims which LTN may suffer from the performance of the Services under this Agreement,
excluding such liabilities arising from gross negligence or willful misconduct by LTN.

 

		9.	Entire Agreement. This Agreement, along with exhibits hereto, constitutes the entire agreement
between the Client and LTN, and supersedes all other oral or written communications, representations, or agreements between LTN
and the Client. This Agreement may be amended only in writing executed by the Client and LTN.

 

		10.	Applicable Law. This Agreement shall be governed by and construed in accordance with the
laws of the State of Colorado and venue shall be exclusive in any state or federal court in Colorado

 

		11.	Severability. If any provision of this Agreement is held to be illegal, invalid or unenforceable
under applicable laws, such provision shall be severable from the remainder of this Agreement, which shall remain in full force
and effect.

 

 

IN WITNESS WHEREOF, the undersigned have
executed this Agreement as of the date first above written.

 

 

	LTN ERGY, LLC	 	Samson Oil and Gas Limited
	 	 	 
	 	 	 
	 	 	 
	/s/ Tristan Farel	 	/s/ Terry Barr, CEO
	Tristan Farel	 	Terry Barr, CEOExhibit 10.1

 

October
3, 2019

 

Bespoke
Extracts, Inc.

323
Sunny Isles Boulevard, Suite 700

Sunny
Isles Beach, FL 33160

 

Ladies and Gentlemen:

 

I hereby exchange $24,000 of accrued but unpaid compensation owed
to me by Bespoke Extracts, Inc. (the “Company”) in exchange for 1 newly created share of Series B Preferred Stock
of the Company, such exchange to be effective upon the Company’s filing of the Certificate of Designation of Series B Preferred
Stock with the Secretary of State of Nevada.

 

Very
truly yours,

  

	/s/ Niquana
Noel	 
	Niquana
Noel	 

   

Acknowledged
and agreed:

 

Bespoke
Extracts, Inc.

 

	By:	/s/ Niquana
Noel	 
	Name: 	Niquana Noel	 
	Title: 	Chief Executive OfficerEX-10.1

 Exhibit 10.1 

AMENDMENT TO OPTION, COLLABORATION AND LICENSE AGREEMENT 

This Amendment (“Amendment”) to the Option, Collaboration and License Agreement dated as of the 19th day of December, 2016 by and between Novartis Pharma AG, a corporation organized and existing under the laws of Switzerland (“Novartis”), and Conatus Pharmaceuticals Inc., a
corporation organized and existing under the laws of the State of Delaware, U.S.A. (“Conatus”), (the “Agreement”), is made and effective as of September 30th, 2019 (the “Amendment Effective Date”).
Any capitalized terms used but not otherwise defined herein shall have the meaning set forth in the Agreement. 
 WITNESSETH 

WHEREAS, Novartis and Conatus entered into the Agreement in order to collaborate on the Conatus Compounds, including
emricasan; 
 WHEREAS, Novartis and Conatus have decided to end their collaboration on the Conatus Compounds; and

 NOW, THEREFORE, in consideration of the foregoing recitals and the mutual covenants and agreements contained
herein, the Parties hereto, intending to be legally bound, do hereby agree as follows: 
  

	 	1.	 The following sections are inserted or amended to read as follows: 

 

	 	1.1	 Insert the following as a new section after 12.5: 

 

	 	    	 12.6 Mutual Termination Of The Collaboration. Novartis and Conatus have decided to terminate
the Agreement as of the Amendment Effective Date. 

  

	 	1.2	 Insert the following as a new section after 13.2: 

 

	 	    	 13.2A Mutual Termination By Conatus and Novartis Of The Collaboration. Upon termination of
this Agreement pursuant to Section 12.6: 

  

	 	(a)	 The License granted to Novartis in Section 2.4 shall terminate and revert to Conatus, and Novartis, its
Affiliates and sublicensees shall not have the right to use, and shall cease the use of, any and all Conatus Technology, including in connection with any Product and/or Combination Product; 

 

	 	(b)	 Novartis will and hereby does grant effective as of the effective date of such termination Conatus a
fully-paid, perpetual, sub-licensable, transferable, perpetual and irrevocable exclusive license under any Novartis Technology developed during the term of this Agreement, and that relates to or enables the
Products, including Novartis’ interest in Joint Patents, to develop, make, have made, use, sell, have sold, offer for sale and import Products (but specifically excluding Combination Products or Novartis Compounds); 

  
 1 

	 	(c)	 The exclusive license granted to Conatus as described in Section 13.2A(b) expressly includes the right
to use clinical and regulatory data solely relating to the applicable Products and information generated by Novartis for regulatory purposes in the format existing and readily available at the time of termination; 

 

	 	(d)	 Novartis will and hereby does assign effective as of the effective date of such termination, at
Novartis’ sole cost (excluding Conatus’ internal costs), to Conatus all of its right, title and interest in and to all United States and foreign regulatory submissions and Regulatory Approvals with respect to the applicable Products and
all drug master files and drug dossiers with respect to the applicable Products (other than those related to Novartis’ manufacturing facilities) and until December 31, 2019, shall reasonably cooperate with Conatus in connection with the
transfer of such Regulatory Approvals from Novartis and/or its Affiliates or sublicensees to Conatus; 

  

	 	(e)	 Novartis shall promptly, unless expressly prohibited by applicable law or any Regulatory Authority, transfer
sponsorship and control, at Novartis’ sole cost, to Conatus of all Ongoing Clinical Trials of Products and Novartis shall continue to be responsible for its share of the costs as specified in Article 5 of the Agreement until December 31,
2019 and reimburse Conatus according to Section 9.1(b); 

  

	 	(f)	 (i) Within fifteen (15) business days following the receipt of an invoice from Conatus, which Conatus
shall deliver to Novartis by January 31, 2020, Novartis shall pay Conatus Novartis’ share of the Development FTE Costs and the Out-Of-Pocket Costs for the
Planned Phase 2b Trials as specified in Article 5 of the Agreement for October 2019, November 2019 and December 2019. Within five (5) business days following the receipt of a monthly invoice from PPD for each of the months September 2019,
October 2019 and November 2019, Conatus shall provide each such invoice to Novartis for information and budget planning purposes; 

  

	 	    	 (ii) If applicable, within fifteen (15) business days following the receipt of an invoice from Conatus,
which Conatus shall deliver to Novartis by January 31, 2020, Novartis shall pay Conatus Novartis’ share of the Development FTE Costs and the Out-Of-Pocket
Costs for the Planned Phase 2b Trials as specified in Article 5 of the Agreement for any accrued but unpaid Development FTE Costs and the Out-Of-Pocket Costs for the
Planned Phase 2b Trials from Q4 2019 and any remaining Development FTE Costs and the Out-Of-Pocket Costs for the Planned Phase 2b Trials for 2020, with such amount being
based on the Out-Of-Pocket Costs Q4 2019 actuals and forecast for 2020 and agreed to in good faith by Novartis and Conatus by January 20, 2020; provided, however,
such invoiced amount invoice to Novartis for any accrued but unpaid costs from Q4 2019 and for 2020 shall not exceed one hundred and fifty thousand USD (US $150,000). 

  
 2 

	 	(g)	 Until December 31, 2019, Novartis shall reasonably cooperate with Conatus, cause its Affiliates to
reasonably cooperate with Conatus and use commercially reasonable efforts to require any Third Party with which Novartis has an agreement with respect to the manufacture and testing of Products (including agreements with contract manufacturing
organizations and contract research organizations), to reasonably cooperate with Conatus in order to accomplish the transfer to Conatus of similar rights as held by Novartis under its agreements with such Third Parties. Novartis shall at
Novartis’ sole cost inform any such Third Party through a letter of authorization for Conatus to contact, as from the Amendment Effective Date, any of Novartis’s Third Parties involved in the manufacture and testing of the Product that
Conatus may consider as reasonably necessary or useful for the manufacture and testing of the Product. For the avoidance of any doubt, any potential transfer of any such material, methods and procedures related to the manufacture and testing of
Products shall be at the sole costs of Conatus. 

  

	 	(h)	 Conatus shall have the right, but not the obligation, to purchase from Novartis some or all of the Conatus
Compound (emricasan) and Clinical Supplies manufactured by Novartis, then in Novartis’ inventory (as listed in Schedule A) free of charge. Conatus shall notify Novartis whether Conatus elects to exercise such purchase right by October 31,
2019. Novartis shall store, at Novartis’ sole cost, such Conatus Compound and Clinical Supplies until November 30, 2019 and, if Conatus does not exercise Conatus’ purchase right, destroy, at Novartis’ sole cost, such Conatus
Compound and Clinical Supplies. For the avoidance of any doubt, Conatus shall be responsible for all costs related to transfer and shipment of the Conatus Compound and Clinical Supplies. The documentation related to the Conatus Compound and Clinical
Supplies will be in the format existing and readily available at the time of termination; 

  

	 	(i)	 Conatus shall have the right, but not the obligation, to take over from Novartis the stability studies for
the Product (including emricasan, as listed in Schedule B). Conatus shall notify Novartis whether Conatus elects to exercise such right by October 31, 2019. Novartis shall store, at Novartis’ sole cost, samples in the stability chambers
until November 30, 2019. Novartis shall not be responsible for the retesting for stability of any Product (including emricasan) expiring during the storage period. If Conatus does not exercise Conatus’ right, Novartis shall destroy, at
Novartis’ sole cost, such stability samples. The documentation related to the stability studies will be in the format existing and readily available at the time of termination; 

  
 3 

	 	(j)	 Conatus shall have the right, but not the obligation to request from Novartis in writing until
November 15, 2019 to transfer information and data as listed in Schedule C. Novartis shall provide to Conatus within forty-five (45) days of such request with a copy in electronic format of the specifically requested documentation as
listed in Schedule C. 

  

	 	(k)	 Except as set forth in this Section 13.2A, the rights and obligations of the Parties hereunder shall
terminate as of the date of such termination. 

  

	 	1.3	 Section 16.3 is deleted in its entirety and replaced by the following: 

16.3 Public Disclosures and Publications Related to Conatus Compounds or Products. Any proposed public disclosure
(whether written, electronic, oral or otherwise) by Conatus relating to any Conatus Compounds or Product that include Novartis authorship shall be provided to Novartis in advance with a reasonable time period for review, and Conatus will take into
account in good faith any Novartis comments; provided, that the foregoing shall not apply to information which is in the public domain, and that this requirement for prior review shall expire after December 31, 2019. 

No other amendments. Except as expressly amended in this Amendment, no other changes are made to this agreement. 

 

	 	2.	 Governing Law. This Amendment will be governed by and construed in accordance with laws of the State
of New York, without giving effect to the conflicts of laws provisions thereof. 

  

	 	3.	 Further Assurances. Novartis and Conatus hereby covenant and agree without the necessity of any
further consideration, to execute, acknowledge and deliver any and all such other documents and take any such other action as may be reasonably necessary to carry out the intent and purposes of this Amendment. 

[signature page follows] 

  
 4 

 IN WITNESS WHEREOF, the Parties hereto have caused this Amendment to
be executed by their duly authorized representatives effective as of the Amendment Effective Date. 
  

			
	 NOVARTIS PHARMA AG

		
	 By:  
	 	 /s/ Gerrard Terlouw, Ph.D., M.B.A.

		 	 Name: Gerrard Terlouw, Ph.D., M.B.A.

		 	 Title: Head BD&L, Immunology, Hepatology & Dermatology

		 	 Date: September 30, 2019

  

			
	 NOVARTIS PHARMA AG

		
	 By:  
	 	 /s/ Eric Hughes, M.D., Ph.D.

		 	 Name: Eric Hughes, M.D., Ph.D.

		 	 Title: Global Development Unit Head, Immunology, Hepatology & Dermatology

		 	 Date: September 30, 2019

  

			
	 CONATUS PHARMACEUTICALS INC.

		
	 By:  
	 	 /s/ Steven J. Mento, Ph.D.

		 	 Name: Steven J. Mento, Ph.D.

		 	 Title: President & Chief Executive Officer

		 	 Date: September 30, 2019

  

			
	 CONATUS PHARMACEUTICALS INC.

		
	 By:  
	 	 /s/ Keith W. Marshall, Ph.D.

		 	 Name: Keith W. Marshall, Ph.D.

		 	 Title: Executive Vice President, Chief Operating Officer & Chief Financial Officer

		 	 Date: September 30, 2019

  
 5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00300-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00300-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00300-of-00352.parquet"}]]